The clinical utility of bronchoalveolar lavage galactomannan result stewardship within a tertiary medical system

Clicks: 15
ID: 319391
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #88 of 159 articles by views in medical mycology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 159 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Our Transplant Infectious Disease (TID) program implemented monitoring of all elevated bronchoalveolar lavage (BAL) galactomannan (GM) results as a quality improvement (QI) project. Twenty-four hours after a positive result, a standardized email is sent to the primary providers if the GM result is unaccounted for based on clinical documentation. We performed a real-world, retrospective study to examine the impact of this intervention over one year (2022-2023) as well as the impact of an elevated BAL GM result on clinical decision-making. We captured the number of positive GM results that triggered notification of the primary team, and the number of times a single positive galactomannan triggered initiation or change of systemic antifungal therapy. We included 55 cases of BAL GM > 1.0. In seventeen cases (31%), a single positive BAL GM result triggered the initiation of antifungal therapy. Most of these cases met criteria for probable IPA. The TID team contacted the primary team for 14 cases (25%) of elevated BAL galactomannan antigens which led to a new start or change in antifungal regimen. Voriconazole was the most common definitive antifungal agent chosen. Though elevated BAL GM results were impactful in introducing or changing antifungal regimens, we identified a possible knowledge gap in the interpretation of elevated galactomannan results among clinical staff. Our study suggests that there may be value in the diagnostic stewardship and monitoring of BAL galactomannan results by infectious diseases clinicians.
Reference Key
openalex_W7166836050 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Anna Apostolopoulou, Sarah P. Hammond, Sarah E. Turbett, Jay A Fishman
Journal medical mycology
Year 2026
DOI
10.1093/mmy/myag069
URL
https://doi.org/10.1093/mmy/myag069
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.